Our course is CME accredited
Longevity Medicine 101 is an approved CME Activity for a maximum of 2.75 AMA PRA Category 1 Credit by the Educational Activities Subcommittee of the Medical Society of Delaware
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Education (ACCME) through the joint providership of the Medical Society of Delaware and Deep Longevity.
Longevity Medicine Course Series
Longevity medicine is a fast-evolving field and it is currently outpacing the ability of the medical practice to internalize and implement the progress of related research. Modern advances in AI and machine learning, biomarker research and drug development have produced numerous tools for early diagnostics and prevention, which remain unknown to the global medical community. The paradigm of longevity and healthy aging as the top priority will undoubtedly greatly impact the primary, secondary and tertiary prevention rates. The Longevity Medicine 101 Course (LMC) is a pivotal curriculum that provides medical professionals with most recent advances in biogerontology, geroscience and precision medicine, while teaching the ways to implement this knowledge in the clinical practice.
The curriculum has been developed by interdisciplinary experts (physicians, academic biogerontologists, AI-experts, computer scientists, KOL in longevity), covering the necessary foundation and most recent scientific evidence.
What Will I Learn?
- The emerging discipline of longevity medicine.
- What are the recent clinical efforts and applications in aging and longevity.
- The role of aging in a variety of diseases.
- A basic introduction to the underlying mechanisms of aging and longevity.
- How to measure aging - introduction to the emerging science of aging clocks and deep aging clocks.
- Understand about geroprotectors and the potential longevity interventions.
- The role of motivation and mindset in aging and longevity.
- Further aging and longevity public information resources and conferences.
What are the requirements and prerequisites?
Some existing knowledge about health sciences and longevity medicine.
Who is this course for?
Medical students, medical doctors, health care professionals pursuing to continue medical education and professionals in biotechnology with no time to waste.
Course Curriculum
- Pre-course Survey
- 01 Course Introduction (4:00)
- 01 Course Guide
- 02 Lecture Notes
- 03 Slide Deck
- 02 Introduction and Core Definitions (7:05)
- 03 What is Longevity Medicine (16:08)
- 04 Epidemiology of Aging (11:18)
- 05 From Biogerontology to Clinic - Geroscience (12:28)
- 06 What is Aging (4:16)
- 07 Mechanisms of Aging (18:18)
- 08 Therapies and Intervention of Longevity (2:13)
- 09 Geroprotectors, Senolytics and Other Phramacologics (31:29)
- 10 Psychology of Aging (8:50)
- 11 Introduction to Biomarkers of Aging and (10:43)
- 12 Deep Aging Clocks (17:05)
- 13 Longevity Network (11:10)
- 14 Deep Longevity and Young.ai (5:35)
- 15 Course Review (2:07)
- 16 Guest Lecture with Morten Scheibye-Knudsen (35:23)
- 17 Patient Life Journey (2:14)
- Course Evaluation Form
- 04 Recommended Reading
- 05 Additional Resources for Learning-designed
- Final Assignment
Course Completion Certificates
Course Completion Certificate
The certificate will be automatically available for print or download after successful completion of the course and passing the final assessment.
MSD CME Accreditation Certificate
The certificate will be automatically available for print or download after successful completion of the course and passing the final assessment.
Our Team
Alex Zhavoronkov, PhD
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. Under his leadership Insilico raised over $52 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical companies achieving millions in immediate revenue and over a billion in potential future milestones and royalties. He is also the founder of Deep Longevity, a company applying deep learning technologies for prediction of human biological age using multiple data types. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic patient data. Since 2012 he published over 130 peer-reviewed research papers, and 2 books. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Evelyne Bischof, MD, PhD
Dr. Evelyne Bischof (prev.Ewelina Biskup), MD. Trained at Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber) and Columbia University NYC, Dr.Bischof is a specialist in internal medicine, with research focus on Artificial Intelligence (AI) and digital health, especially in the fields of oncology, preventative and precision medicine, biogerontology, and geronto-oncology. She is also a longevity physician at Human Longevity and board member of various internal medicine societies. She published over 50 peer-reviewed papers, and is a frequent speaker at scientific and medical conferences. She spent a decade practicing medicine, lecturing at medical schools and performing clinical and translational research in New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: Fudan Cancer Institute and Hospital, Shanghai; Zhongshan Hospital (Fudan University), Renji Hospital (Jiaotong University) and Shanghai East Hospital (Tongji University).
Professor Alexey Moskalev
Prof. Alexey Moskalev is a Corresponding Member of Russian Academy of Sciences, Doctor of Biology, the Head of the Laboratory of Geroprotective and Radioprotective Technologies in the Institute of Biology of Federal Research Center 'Komi Scientific Centre' of the Ural Branch of the Russian Academy of Sciences, the Head of the Department of Ecology of the Syktyvkar State University named after Pitirim Sorokin. He is the author of more than 100 publications in the area of genetics of aging and longevity and radiation genetics. He is a member of the editorial boards of Ageing research reviews, Aging, Biogerontology, Frontiers in Genetics of Aging, Aging and disease, Gerontology, Advances in Gerontology. He established the series of the International Symposiums “Genetics of Aging and Longevity” (Syktyvkar 2008, 2010, Moscow 2012, Sochi 2014), “Biomedical Innovation For Healthy Longevity” (Saint Petersburg 2016), “Interventions to extend healthspan and lifespan” (Kazan 2018), “Longevity interventions 2020” (Ekaterinburg, 2020).
Morten Scheibye-Knudsen, MD, PhD
Dr. Morten Scheibye-Knudsen, associate professor, University of Copenhagen. According to him "Aging is the largest risk factor for most diseases and damage to our genome is likely the cause of aging". He is focused on exploring the physiological consequences of DNA damage and what we can do to intervene in genotoxic insults. His goal is to understand, modulate, and perhaps treat aging and age-related diseases. Morten earned his MD in 2007 from the University of Copenhagen where he also earned his DMSc (Doctor of Medical Sciences, higher doctorate) in Neurodegeneration in Accelerated Aging in 2016.
Longevity Testimonials
Elena B., MD
This educational course is excellent, it is helping me to understand a lot more. It is very informative, well-structured. The provided information is extremely helpful. Keep up the great work! Keep doing and inspiring.
Aneil M.
Absolutely excellent. Speaking as a technology entrepreneur and former researcher at Harvard Systems Biology, I'm pleasantly surprised to see such a far reaching vision being introduced to doctors.
Christopher M., MD
I'm a physician trained in functional medicine interested in longevity medicine and the role of AI in helping physicians like me helping people slow or reverse aging. This course is an awesome introduction and overview of the terminology and major concepts in longevity science.
According to the United Nations, the proportion of people aged over 65 now outnumber children younger than 5. The enormous growth in the elderly population is posing a socioeconomic challenge to societies worldwide, and necessitates new sweeping interventions for age-associated diseases. This year we have an incredibly exciting program with global thought-leaders sharing their latest insights into aging and how we target aging process ensuring everyone lives a healthier and longer life. Welcome to the 8th Aging Research and Drug Discovery Meeting.
The 9th annual Aging Research and Drug Discovery Meeting is a non-profit conference
The ARDD Meeting has grown a great deal in a relatively short time: from a small forum in 2014 to a separate and independent meeting with over 2k delegates in 2020. From its start as a small forum during EMBO Conference, ARDD has expanded, including short talks of young scientists, industry panel discussions, workshops (NEW in 2021) and a student ambassadors program (NEW in 2021).
From 2014 till 2019 the ARDD Meeting was a part of bigger conferences (EMBO and Basel Life), in 2020 ARDD became an independent event. For most of its history, ARDD has been run on a shoestring with some support from our extensive close collaborators and KOLs in the field. From 2020 all the expenses, including travel and venue costs have to be covered by the ARDD organisers.
Recommended Reading
The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy
